Declaration of interests
T Okusaka is supported by a consulting/advisory relationship with Taiho Pharmaceutical, Daiichi Sankyo, Sumitomo Dainippon Pharma, Bristol Myers Squibb, AstraZeneca, Eisai, and Nihon Servier; research funding from Eli Lilly Japan, MSD, AstraZeneca, Eisai, Chugai Pharmaceutical, Novartis Pharma, Sumitomo Dainippon Pharma, Bristol Myers Squibb, Taiho Pharmaceutical, and Baxter; honoraria from Meiji Seika Pharma, Teijin Pharma, Eli Lilly Japan, MSD, AstraZeneca, AbbVie, Eisai, Ono Pharmaceutical, Yakult Honsha, Daiichi Sankyo, Chugai Pharmaceutical, Nihon Servier, and Novartis Pharma; and scientific advisory board fees from AstraZeneca, Nippon Shinyaku, Nihon Servier, Novartis Pharma, Pfizer, and Mundipharma. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.